The study cohort consisted of a total of 120 subjects, including healthy elderly controls, patients with mild cognitive impairment and patients with Alzheimer’s disease. Baseline and two-year longitudinal samples from DiaGenic’s clinical multicenter studies and biobank were used for the study.
“A blood-based test that will allow community doctors to diagnose or refer patients to specialists at the earliest stages of Alzheimer’s disease will be crucial to attaining the ultimate goal of preventing the onset of clinical dementia signs and symptoms," says Sam Gandy, Professor of Neurology and Psychiatry and Director, Mount Sinai Alzheimer's Disease Research Center. Dr. Gandy is as Scientific Advisor to DiaGenic, but was not involved in the The study cohort consisted of a total of 120 subjects, including healthy elderly controls, patients with mild cognitive impairment and patients with Alzheimer’s disease. Baseline and two-year longitudinal samples from DiaGenic’s clinical multicenter studies and biobank were used for the study.
“A blood-based test that will allow community doctors to diagnose or refer patients to specialists at the earliest stages of Alzheimer’s disease will be crucial to attaining the ultimate goal of preventing the onset of clinical dementia signs and symptoms," says Sam Gandy, Professor of Neurology and Psychiatry and Director, Mount Sinai Alzheimer's Disease Research Center. Dr. Gandy is as Scientific Advisor to DiaGenic, but was not involved in the study.
He added: "Such a test will also be essential to drug development by enabling the identification of high risk subjects at preclinical stages so that they can be enrolled in drug trials by pharmaceutical companies and academic laboratories as we seek to develop an effective disease-modifying therapy for Alzheimer's disease. If DiaGenic's biomarkers are validated and subsequently approved by the applicable regulatory authorities, this test panel has the potential to speed trial recruitment, to reduce trial size and costs, and to form an important cornerstone of our successful approach to this emotionally and economically devastating illness."
“Early identification of patients with mild cognitive impairment who will go on to develop Alzheimer’s dementia has the potential to significantly reduce drug development costs”, said DiaGenic CEO Erik Christense. “These findings demonstrate the strengths of DiaGenic’s technology and expertise within blood-based CNS biomarkers. DiaGenic’s strong IP portfolio linked to measuring gene expression in blood makes us unique,” Dr Christensen adds.
The study results will be presented at 4th Conference Clinical Trial on Alzheimer's Disease, 3–5th November - San Diego, CA, USA.study.